Secondly, early clinical trials have revealed unexpectedly limited benefits of c-Met inhibition [27], and the side effects caused by c-Met inhibitors, including anemia, neutropenia, and liver and bone marrow toxicity [34,35] have been observed frequently. Here, MET is linked to anemia (phenotype).